These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35032384)

  • 21. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyslipidemia and atypical antipsychotic drugs.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 18():27-35. PubMed ID: 15600382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study.
    Arango C; Bobes J; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2008 Sep; 104(1-3):1-12. PubMed ID: 18606526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus.
    Wu CS; Gau SS
    Schizophr Bull; 2016 May; 42(3):703-11. PubMed ID: 26721264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine versus typical neuroleptic medication for schizophrenia.
    Wahlbeck K; Cheine M; Essali MA
    Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased cardiovascular risk with second-generation antipsychotic agent switches.
    Ried LD; Renner BT; McConkey JR; Bengtson MA; Lopez LM
    J Am Pharm Assoc (2003); 2006; 46(4):491-8; quiz 499-501. PubMed ID: 16913393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 28. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
    Citrome L; Holt RI; Walker DJ; Hoffmann VP
    Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of antipsychotics on mortality in schizophrenia: systematic review.
    Weinmann S; Read J; Aderhold V
    Schizophr Res; 2009 Aug; 113(1):1-11. PubMed ID: 19524406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid profile in schizophrenia: case control study.
    Mhalla A; Bel Hadj Salah W; Mensi R; Amamou B; Messaoud A; Gassab L; Douki W; Najjar MF; Gaha L
    Tunis Med; 2018 Jan; 96(1):22-29. PubMed ID: 30324988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential metabolic effects of antipsychotic treatments.
    Haupt DW
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S149-55. PubMed ID: 16872808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.
    Nielsen J; Skadhede S; Correll CU
    Neuropsychopharmacology; 2010 Aug; 35(9):1997-2004. PubMed ID: 20520598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular disease in patients with schizophrenia.
    Kritharides L; Chow V; Lambert TJ
    Med J Aust; 2017 Feb; 206(2):91-95. PubMed ID: 28152356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
    Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
    Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
    Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
    BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic risk factor-profile in patients on treatment with second generation antipsychotics.
    Zahan T; Akhter N; Mullick MSI; Dewan ZF
    Bangladesh Med Res Counc Bull; 2015 Dec; 41(3):144-150. PubMed ID: 29870170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.